Announces Strategic Investment in Omniscope
Summary
Through proprietary laboratory technology and AI, Omniscope is building the worlds largest Immune Databank This transaction proves Buenavistas continued commitment to leverage its expertise in Artificial Intelligence, Deep Tech and HealthcareBuenavista Equity Partners, a private equity group specialising in the lower/mid-market segment in Spain, announced today its strategic investment in Omniscope, a fast-growing technology company at the crossroads of biotechnology and data science decoding the immune system. Co-founded by Vijay Vaswani, Holger Heyn and Lynnette Ang, Omniscope has quickly established itself as a leader in empowering key decision makers in the medical sector with cutting-edge data insights through its innovative platform.Omniscope leverages proprietary technology to build the worlds largest immune databank, generating high-resolution immune insights to inform therapy and develop diagnostics through a convergence of deep immune profiling and advanced Artificial Intelligence. Omniscopes platform is already transforming how industriesfrom healthcare to retailleverage data to drive decisions and create value.We are thrilled to partner with Omniscope and its visionary co-founders, Vijay, Holger and Lynnette, whose leadership and technical expertise have been instrumental in building a truly groundbreaking solution, said Joaquim Hierro, Managing Director at Buenavista Ventures. Their support will enable us to expand our capabilities, reach more customers globally, and continue pushing the boundaries of immune data intelligence.With 150 million under management in 2023, the funds in the Buenavista Ventures area focus their investment on startups and entrepreneurs fostering technological and digital innovation. This investment marks Buenavista Equity Partners continued commitment to leverage its expertise in Artificial Intelligence, Deep Tech and Healthcare, supporting innovative companies that redefine industries and deliver long-term value.